Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Jun 23, 2023 7:07pm
461 Views
Post# 35512297

Thoughts on pan can deal

Thoughts on pan can dealAs Ionc noted, pan can picked us to be in their trials.

Some have asked on ST what this means? Is it a lesser step forward than a big pharma partner?

My view: no, it is a much better deal for us. We give up nothing and get a free trial with the best of the best for a new standard of care. If that trial works well, we will be the SOC for the onco virus for panc. 

This agreement with pan can postpones our need to find a big pharma partner, and provides ONCY with more value to bring to a future deal. Roche should be salivating at the thought of tecntriq being the CI that goes into the pan can trials. So that is a bigger incentive for them to throw in with us with an equity deal or a buy out.

One poster who is on here and ST note that it seems likely we are getting offers but we are holding out for OS date for mBC and panc as well as more results on CRC and CAR-T before making a deal. That makes sense to me, given our results. And make no mistake, our results are more than stellar. They are amazing in panc, so far at least in terms of responses to treatment, although we have not got the OS or PFS results as yet, IIRC.

I was disappointed at the plunge in price at 11:30 today, but it is Friday, nothing goes up for ever, and there we profits to be taken for those who trade. The fact is that something like 13 mil shares changed hands. That means there are buyers out there, and lots more interest than we have seen since I have been here, roughly 10 years ago. 


<< Previous
Bullboard Posts
Next >>